EGFR and non-small cell lung carcinoma: Icotinib, a highly specific EGFR tyrosine kinase inhibitor (EGFR-TKI), has demonstrated notably high clinical effectiveness and safety performance for the patients with non-small cell lung cancer (NSCLC) (Liu S. M. et al., 2023).